BioSkryb, a Durham, N.C.-based single cell genome sequencing company, raised $11.5M in seed funding.
The round was led by Anzu Partners with participation from law firm Wilson Sonsini Goodrich & Rosati.
The company intends to use the funds to accelerate its product roadmap and its commercialization efforts to enable enhanced levels of genomic and transcriptomic analyses for translational research and clinical diagnostics.
Led by Jay West, PhD, cofounder and Chief Executive Officer, and Charles Gawad, MD/PhD, cofounder, BioSkryb is a developer of genomic amplification technologies that deliver higher coverage and fidelity for gene sequencing. The company’s proprietary genomic amplification technology allows scientists working with scarce genetic material to achieve high quality gene sequencing data. The technology provides uniform coverage of almost the entire genome, allowing for accuracy in DNA variant calling. It will support a new wave of single cell and low DNA input genomics applications in diverse areas of life sciences research, including cancer biology, microbiology, and genetics.
The company also announced that it has appointed William E. Evans, PharmD and Siddhartha C. Kadia, PhD to its Board of Directors. Dr. Evans served as St. Jude Children’s Research Hospital’s fifth President and CEO from 2004 to 2014 and currently holds the St. Jude Endowed Chair in Pharmacogenomics. Dr. Kadia previously served as President and CEO of EAG Laboratories in San Diego, CA, and President, Life Sciences Division at Life Technologies Corporation, a company that was acquired by Thermo Fisher in 2014.
FinSMEs
09/01/2020